Hepatitis C Virus Prevalence and Incidence in a Large Nationwide Sample of Patients in Opioid Substitution Treatment in Germany: A Prospective Cohort Study
Authors:
Open Access
- 21 October 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 70 (10) , 2199-2205
Abstract
Background: Hepatitis C virus (HCV) infection is highly prevalent among people who inject drugs (PWID). Accurate data on HCV prevalence and incidence rates among patients receiving opioid substitution treatment (OST) are needed to estimate the current and future burden of HCV infections in this high-risk population. Methods: Baseline data from routine care were collected between October 2014 and June 2016 from randomly selected OST facilities in Germany. The primary outcome measure was the HCV status (antibody and RNA prevalence). Patients who were HCV antibody–negative at baseline were followed up after 12 months to calculate the HCV incidence rate. Results: Sixty-three facilities from 14 German Federal States provided clinical data for a total of 2466 OST patients. HCV antibody and HCV RNA prevalence were 58.8% (95% confidence interval [CI], 56.8%–60.8%) and 27.3% (95% CI, 25.5%–29.2%), respectively. At baseline, a total of 528 patients (21.4%) had previously undergone antiviral treatment. Moreover, lower HCV RNA prevalence was associated with female gender, employment, younger age, and shorter duration of OST and opioid dependence. The HCV incidence rate was 2.5 cases per 100 person-years. Conclusions: The low HCV RNA prevalence and HCV incidence rates confirm that OST in Germany is an effective setting both for treating chronic HCV infections and for preventing new infections among PWID. Scaling up the provision of OST, HCV testing, and HCV treatment among OST patients are important public health strategies for reducing HCV infections in this high-risk population.Keywords
Funding Information
- Janssen-Cilag GmbH
This publication has 35 references indexed in Scilit:
- The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug usersAddiction, 2014
- Interventions to prevent HIV and Hepatitis C in people who inject drugs: A review of reviews to assess evidence of effectivenessInternational Journal of Drug Policy, 2014
- Combination Interventions to Prevent HCV Transmission Among People Who Inject Drugs: Modeling the Impact of Antiviral Treatment, Needle and Syringe Programs, and Opiate Substitution TherapyClinical Infectious Diseases, 2013
- Epidemiology and natural history of HCV infectionNature Reviews Gastroenterology & Hepatology, 2013
- Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross‐sectional survey dataJournal of Viral Hepatitis, 2013
- Hepatitis C prevalence in injecting drug users in Europe, 1990–2007: impact of study recruitment settingEpidemiology and Infection, 2012
- HCV Routes of Transmission: What Goes Around Comes AroundSeminars in Liver Disease, 2011
- Low Risk for Hepatitis C Seroconversion in Methadone Maintenance TreatmentJournal of Addiction Medicine, 2011
- The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidenceAddiction, 2011
- Psychopathological changes and quality of life in hepatitis C virus‐infected, opioid‐dependent patients during maintenance therapyAddiction, 2009